Lantheus (NASDAQ:LNTH) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Lantheus stock on January 8th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of ICF International NASDAQ: ICFI on 2/3/2025.
• Purchased $15,001 - $50,000 in shares of CACI International NYSE: CACI on 1/31/2025.
• Purchased $50,001 - $100,000 in shares of Hawaiian Electric Industries NYSE: HE on 1/31/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Agios Pharmaceuticals NASDAQ: AGIO on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Paragon 28 NYSE: FNA on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of U.S. Physical Therapy NYSE: USPH on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 1/29/2025.

Lantheus Price Performance

LNTH traded down $2.02 during trading hours on Friday, reaching $79.94. 737,336 shares of the stock traded hands, compared to its average volume of 709,331. The company has a market cap of $5.56 billion, a price-to-earnings ratio of 13.30 and a beta of 0.44. Lantheus Holdings, Inc. has a fifty-two week low of $56.06 and a fifty-two week high of $126.89. The firm's fifty day simple moving average is $91.43 and its two-hundred day simple moving average is $97.66.

Remove Ads

Institutional Trading of Lantheus

Hedge funds have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new stake in Lantheus in the 3rd quarter valued at about $25,000. Kestra Investment Management LLC bought a new stake in Lantheus in the 4th quarter valued at about $27,000. Signaturefd LLC raised its position in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after buying an additional 92 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of Lantheus during the 4th quarter worth about $37,000. Finally, UMB Bank n.a. raised its position in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after buying an additional 126 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on LNTH shares. JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, Truist Financial restated a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $131.86.

Insiders Place Their Bets

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.50% of the stock is owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.